We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Daiwa America upgraded shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) from a hold rating to a strong-buy rating in a ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases Bristol Myers reports promising preliminary results for its next-gen CAR T ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its price target increased by Morgan Stanley from $36.00 to $39.00 in a research note issued to investors on Tuesday,Benzinga reports.

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.95 which represents a slight increase of $0.50 or 0.90% from the prior close of $55.45. The stock opened at ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $ ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...